SCHEMBL3528317

SCHEMBL3528317

COC(=O)CCC#Cc1cc(Cl)ccc1NS(=O)(=O)c1cccc(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 1/20 0.49
KEAP1 Q14145 2/20 0.49
NFE2L2 Q16236 2/20 0.49
FLT1 P17948 1/20 0.48
FLT4 P35916 1/20 0.48
KDR P35968 1/20 0.48
PGR P06401 2/20 0.44
SLC20A2 Q08357 1/20 0.43
SLC20A1 Q8WUM9 1/20 0.43
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 1/20 0.42
KDM1A O60341 1/20 0.42
MAOA P21397 1/20 0.42
MEP1B Q16820 1/20 0.42
LMNA P02545 2/20 0.42
ALDH1A1 P00352 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3527759 0.94 SLC16A3 (0.48) SLC16A3KEAP1NFE2L2FLT1FLT4
SCHEMBL3522957 0.89 FLT1 (0.43) FLT1FLT4KDRKMT2AMAPT
SCHEMBL3527490 0.89 LMNA (0.53) SLC16A3KEAP1NFE2L2FLT1FLT4
SCHEMBL3523698 0.89 ERBB2 (0.50) MEN1KMT2AMAPTGAALMNA
SCHEMBL3525803 0.87 ALDH1A1 (0.48) MEN1KMT2AMAPTGAALMNA
SCHEMBL3522938 0.86 ALDH1A1 (0.53) SLC16A3MEN1KMT2AALDH1A1CCR9
SCHEMBL3521484 0.86 SLC20A2 (0.51) SLC20A2SLC20A1MEN1KMT2AGAA
SCHEMBL3523907 0.86 CYP2C9 (0.47) PGRCCR9
SCHEMBL3527669 0.84 LMNA (0.48) KMT2AMAPTLMNAALDH1A1HTT
SCHEMBL3529261 0.84 CCR9 (0.43) KMT2AMAPTLMNAALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP SLC16A3 3744/4885KEAP1 292/4885NFE2L2 618/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG SLC16A3 3322/4885KEAP1 867/4885NFE2L2 678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.